Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 7/20 | 0.38 |
| ▸ | NOS2 | P35228 | 6/20 | 0.38 |
| ▸ | NOS1 | P29475 | 6/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19710952 | 0.83 | NOS3 (0.35) | NOS3NOS2NOS1 | |
| SCHEMBL19678816 | 0.79 | NOS3 (0.33) | NOS3NOS2NOS1 | |
| SCHEMBL10375772 | 0.77 | LMNA (0.43) | NUDT1MEN1KMT2ANOS3NOS2 | |
| SCHEMBL171325 | 0.77 | — | — | |
| SCHEMBL2757263 | 0.76 | KMT2A (0.61) | NUDT1MEN1KMT2ATSHRTAAR1 | |
| SCHEMBL16543303 | 0.74 | NOS2 (0.40) | MEN1KMT2ANOS3NOS2NOS1 | |
| SCHEMBL1369489 | 0.73 | KMT2A (0.52) | NUDT1MEN1KMT2ATSHRTAAR1 | |
| SCHEMBL11190041 | 0.73 | MEN1 (0.42) | NUDT1MEN1KMT2ATSHRTAAR1 | |
| SCHEMBL9413906 | 0.72 | TSHR (0.41) | NUDT1MEN1KMT2ATSHR | |
| SCHEMBL1576638 | 0.70 | NUDT1 (0.65) | NUDT1MEN1KMT2ATSHRSMPD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023229685-A2 | BROAD-SPECTRUM INHIBITORS OF CYTOMEGALOVIRUS | MICROBIOTIX, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-0019811-A1 | Pyrimidine compounds, process for their preparation, pharmaceutical compositions containing them and their therapeutical use | CIBA-GEIGY AG (CH) | 1980-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | NUDT1 25/4885MEN1 2093/4885KMT2A 2226/4885 |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | GPR119, HCRTR2, MCHR1 | NUDT1 96/4885MEN1 2494/4885KMT2A 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.